Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

65.94USD
22 Feb 2018
Change (% chg)

$-0.59 (-0.89%)
Prev Close
$66.53
Open
$67.00
Day's High
$67.00
Day's Low
$65.87
Volume
1,798,219
Avg. Vol
1,770,703
52-wk High
$70.04
52-wk Low
$51.56

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

BRIEF-Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb

* SIRENAS ENTERS INTO MULTI-TARGET COLLABORATION WITH BRISTOL-MYERS SQUIBB

12 Feb 2018

Roche notches fresh win amid crowd of immunotherapy cocktails

ZURICH Roche's Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker's immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals.

06 Feb 2018

Roche notches fresh win amid crowd of immunotherapy cocktails

ZURICH Roche's Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker's immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals.

06 Feb 2018

Roche notches fresh win amid crowd of immunotherapy cocktails

ZURICH, Feb 6 Roche's Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker's immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals.

06 Feb 2018

UPDATE 4-Bristol-Myers' positive cancer data still lags Merck

Feb 5 Bristol-Myers Squibb Co on Monday provided some positive data on its immuno-oncology drugs for the most lucrative lung cancer market but it fell short of giving clarity on its ability to compete with a rival treatment from Merck & Co Inc

05 Feb 2018

BRIEF-Bristol-Myers Squibb Sees 2018 Non-GAAP Tax Rate 20-21

* SEES 2018 NON-GAAP TAX RATE 20-21%, SEES TAX RATE DROPPING TO HIGH TEENS IN "COMING YEARS" Further company coverage: (Reporting By Michael Erman)

05 Feb 2018

BRIEF-Bristol-Myers Squibb Says Key Lung Cancer Trial Meets Main Goal

* PIVOTAL PHASE 3 CHECKMATE -227 STUDY DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL (PFS) WITH THE OPDIVO PLUS YERVOY COMBINATION VERSUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH HIGH TUMOR MUTATION BURDEN (TMB)

05 Feb 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.91 0.00
Pfizer Inc. (PFE.N) $35.74 -0.02
Merck & Co., Inc. (MRK.N) $54.57 +0.02
Sanofi SA (SASY.PA) €64.89 +0.19
AstraZeneca plc (AZN.L) 4,772.00 -27.50
GlaxoSmithKline plc (GSK.L) 1,303.00 -21.60
Eli Lilly and Co (LLY.N) $77.19 -0.36
Roche Holding Ltd. (ROG.S) CHF223.30 -0.20
Roche Holding Ltd. (RO.S) CHF226.40 -1.20

Earnings vs. Estimates